NCT01268488

Brief Summary

The purpose of this study is to evaluate the performance of an investigational blood glucose meter with the Contour sensor strip. It was decided that this investigational monitoring system would not be part of a regulatory submission and it will not proceed to marketed product.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
98

participants targeted

Target at P50-P75 for not_applicable diabetes

Timeline
Completed

Started Dec 2010

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2010

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2010

Completed
28 days until next milestone

First Submitted

Initial submission to the registry

December 29, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 31, 2010

Completed
1.8 years until next milestone

Results Posted

Study results publicly available

October 16, 2012

Completed
Last Updated

November 3, 2016

Status Verified

September 1, 2016

Enrollment Period

Same day

First QC Date

December 29, 2010

Results QC Date

September 14, 2012

Last Update Submit

September 28, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Numbers of Fingerstick Blood Glucose (BG) Results Within +/- 5 to 15mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method

    Subjects with diabetes tested subject fingerstick blood using an investigational blood glucose meter (BGM). BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer. BG results were used to calculate the number of BG results within +/- 5 to 15 mg/dL (for reference BG results \<75mg/dL) or +/- 5 to 20% (for reference BG results \>=75mg/dL) of the reference method results.

    2 hours

Secondary Outcomes (3)

  • Numbers of Palm Blood Glucose (BG) Results Within +/- 5 to 15 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method

    2 hours

  • Number of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Comprehension)

    2 hours

  • Numbers of Forearm Blood Glucose (BG) Results Within +/- 5 to 15 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method

    2 hours

Study Arms (1)

Intended Users of the System

EXPERIMENTAL

Untrained subjects with diabetes obtained capillary fingerstick, palm, and forearm blood and performed Blood Glucose (BG) tests using a Ninja 2 investigational blood glucose meter and the Contour® sensor. This BG monitoring system will not proceed to marketed product.

Device: Ninja 2 Investigational Blood Glucose Meter

Interventions

Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.

Intended Users of the System

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males and females, 18 years of age and above
  • Type 1 or type 2 diabetes
  • Currently self-testing blood glucose at home at least twice daily
  • Able to speak, read, and understand English
  • Willing to complete all study procedures

You may not qualify if:

  • Currently Pregnant
  • Hemophilia or any other bleeding disorder
  • Employee of competitive medical device company
  • Cognitive disorder or other condition which, in the opinion of the investigator, would put the person at risk or seriously compromise the integrity of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Consumer Product Testing Company

Fairfield, New Jersey, 07004, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Limitations and Caveats

It was decided that this investigational BG monitoring system would not be part of a regulatory submission. It will not proceed to market.

Results Point of Contact

Title
Carmine Greene, Senior Clinical Research Scientist
Organization
Ascensia Diabetes Care

Study Officials

  • Michael Caswell, PhD

    Consumer Product Testing Company

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
GT60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 29, 2010

First Posted

December 31, 2010

Study Start

December 1, 2010

Primary Completion

December 1, 2010

Study Completion

December 1, 2010

Last Updated

November 3, 2016

Results First Posted

October 16, 2012

Record last verified: 2016-09

Locations